From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade names Minnebro
Synonyms CS-3150; XL-550
Routes of
By mouth
Drug class Antimineralocorticoid
CAS Number
  • 1632006-28-0
PubChem CID
  • 25052023
  • 28666733
  • N62TGJ04A1
  • D10892
  • ChEMBL2181932
Chemical and physical data
Formula C22H21F3N2O4S
Molar mass 466.475 g/mol g·mol−1
3D model (JSmol)
  • Interactive image

Esaxerenone (INN) (brand name Minnebro; developmental code names CS-3150, XL-550) is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and developed by Daiichi Sankyo Company and is approved in Japan for the treatment of hypertension.[1][2][3] It acts as a highly selective silent antagonist of the mineralocorticoid receptor (MR), the receptor for aldosterone, with greater than 1,000-fold selectivity for this receptor over other steroid hormone receptors, and 4-fold and 76-fold higher affinity for the MR relative to the existing antimineralocorticoids spironolactone and eplerenone.[1][2][3] As of January 2019, esaxerenone is in phase III clinical trials for diabetic nephropathies.[1]

See also


  1. ^ a b c
  2. ^ a b Yang J, Young MJ (2016). "Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences". Curr Opin Pharmacol. 27: 78–85. doi:10.1016/j.coph.2016.02.005. PMID 26939027.
  3. ^ a b Kolkhof P, Nowack C, Eitner F (2015). "Nonsteroidal antagonists of the mineralocorticoid receptor". Curr. Opin. Nephrol. Hypertens. 24 (5): 417–24. doi:10.1097/MNH.0000000000000147. PMID 26083526.

External links

  • Esaxerenone - AdisInsight

Retrieved from ""
This content was retrieved from Wikipedia :
This page is based on the copyrighted Wikipedia article "Esaxerenone"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA